Navigation Links
Lpath, Inc. CEO Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Date:5/9/2011

NEW YORK, May 9, 2011 /PRNewswire/ -- Lpath, Inc. (OTC: LPTN), the category leader in bioactive-lipid-targeted therapeutics, today announced that their May 5th RetailInvestorConferences.com presentation is available for on-demand viewing.

LINK: www.retailinvestorconferences.com > Click the red "register/ watch event now" button.

Lpath, Inc.'s presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

About Lpath, Inc.

San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2(TM) drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, two of which -- ASONEP(TM) for cancer and iSONEP(TM) for wet AMD -- have completed Phase 1 clinical trials. Lpath entered into an agreement with Pfizer in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit www.Lpath.com.

About RetailInvestorConferences.com:

RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

Forward-Looking Statements

The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the eventual commercial viability of the Company's drug programs; the eventual revenues that the Company would attain if the drug eventually gets approved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the results of any future clinical trials for iSONEP may not be favorable and the Company may never receive regulatory approval for iSONEP; and the Company may not be able to secure the funds necessary to support its clinical trial and product development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Lpath, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Technest Holdings, Inc. to Acquire AccelPath, LLC; Issue Contingent Value Rights to Common Stockholders; and Issue Shares of Its Series E 5% Convertible Preferred Stock
2. Lpath, Inc. CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
3. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
4. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
5. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
6. Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)
7. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
8. Spectrum Pharmaceuticals Announces Presentation of SPI-1620 Data at the AACR-NCI-EORTC International Conference
9. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
10. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
11. IDM Pharma Announces Upcoming Clinical Data Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... IRVING, Texas , Sept. 7, 2017 /PRNewswire/ ... molecular science focused on fulfilling the promise of ... that further validate the benefits of its molecular ... Each study utilized comprehensive genomic profiling plus (CGP+) ... each individual patient,s tumor on a molecular level, ...
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... Ecocor , ... Richard Pedranti Architect (RPA), a full-service architecture firm focusing on sustainable design, ... Line of Model Homes . Independently, Ecocor and RPA have extensive experience with ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... inaugural SABRE Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student ... MS in Educational Leadership and Administration at St. Thomas University in Miami, Florida, ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Cursed with a Curse: ... tithe, and the freedom experienced when breaking free from this misconception. “Cursed with ... M. Harrison. , Published by Christian Faith Publishing, Lysa M. Harrison’s new book ...
(Date:9/22/2017)... ... , ... "Success Files," a short- and long-form documentary style ... disease estimated to affect the lives of more than 5 million Americans living ... leading voice in the fight for cure and research into the disease, its ...
(Date:9/22/2017)... ... 2017 , ... “Letters From Home”: a moving compilation of letters that ... God. “Letters From Home” is the creation of published author, John Allred, a passionate ... Jerry Savelle Ministries International, who has traveled and ministered on four continents. , “It ...
Breaking Medicine News(10 mins):